DNLI
Denali Therapeutics Inc.
OpenVolumeMkt capP/EEPSDiv yield
Day – 52-wk –
Expected move
InputsNext report
Last report
Largest filed tie
13F top-10 QoQ
Top fund weight
Fund move
Fund move
Last report0 of 8 at or beyond impliedshaded = implied▲▼ = realized× = |realized| ÷ implied
+0.40%
vs ±9.8% implied · ×0.04
shaded = implied · ▲▼ = realized
No thesis.
Denali Therapeutics Inc.
19.01
Linked news
| Rank | Manager | Value | % 13F | ||
|---|---|---|---|---|---|
| 1 | T. Rowe Price Investment ManagementT. Rowe Price | $416.1M | 10.28% | +89.91% | |
| 2 | BlackRockBlackRockindex-like | $360.8M | 8.91% | +7.61% | |
| 3 | Baillie GiffordBaillie Gifford | $307.6M | 7.60% | −0.88% | |
| 4 | State StreetState Streetindex-like | $181.3M | 4.48% | +12.39% | |
| 5 | Temasek Holdings (Private)Temasek Holdings (Private) | $180.4M | 4.45% | 0.00% | |
| 6 | Vanguard Portfolio ManagementVanguard Portfolioindex-like | $166.6M | 4.11% | +5.83% | |
| 7 | Vanguard Capital ManagementVanguardindex-like | $161.4M | 3.99% | +2.08% | |
| 8 | FMRFMR | $116.7M | 2.88% | −0.86% | |
| 9 | Goldman Sachs GroupGoldman Sachs | $106.9M | 2.64% | −5.70% | |
| 10 | Geode Capital ManagementGeodeindex-like | $102.2M | 2.52% | +6.61% | |
| 11 | Holocene AdvisorsHolocene | $100.4M | 2.48% | +22.21% | |
| 12 | Baker Bros. AdvisorsBaker Bros. | $96.0M | 2.37% | +0.07% | |
| 13 | UBS Asset Management AmericasUBS Asset Management Americas | $81.3M | 2.01% | −28.66% | |
| 14 | T. Rowe Price AssociatesT. Rowe Price | $80.7M | 1.99% | +27.27% | |
| 15 | UBS GroupUBS | $80.3M | 1.98% | +21.36% | |
| 16 | AlliancebernsteinAlliancebernstein | $76.8M | 1.90% | +3.15% | |
| 17 | Dimensional Fund AdvisorsDimensional | $73.6M | 1.82% | +6.26% | |
| 18 | Norges BankNorges Bankindex-like | $72.7M | 1.79% | — | |
| 19 | Pictet Asset Management HoldingPictet | $71.9M | 1.78% | +9.08% | |
| 20 | Capital Research Global InvestorsCapital Research Global Investors | $66.0M | 1.63% | +2.04% | |
| 21 | Fisher Asset ManagementFisher | $62.1M | 1.53% | −0.93% | |
| 22 | Delaware Management HoldingsDelaware | $56.8M | 1.40% | +1828.21% | |
| 23 | Casdin CapitalCasdin Capital | $52.6M | 1.30% | +11.14% | |
| 24 | Crestline ManagementCrestline | $49.1M | 1.21% | −13.57% | |
| 25 | Principal Financial GroupPrincipal Financial | $36.5M | 0.90% | −3.95% |
296 managers report $4.0B of Denali Therapeutics on form 13F for the quarter ended Jun 30 '26. 28 of them hold 80% of it; T. Rowe Price is largest at 10.28%.
Expected move
Inputs8Q avg ±3.1%·×4.52·rich
straddle ±17.6%
spot 18.94exp Nov 20ATM strike 20ATM straddle 3.93IV 103%